Hikma Pharmaceuticals Plc (HIK) Given Consensus Rating of “Hold” by Analysts

Shares of Hikma Pharmaceuticals Plc (LON:HIK) have been given an average recommendation of “Hold” by the eleven ratings firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is GBX 1,551.45 ($20.40).

A number of equities analysts have weighed in on HIK shares. Jefferies Group LLC decreased their target price on Hikma Pharmaceuticals Plc from GBX 1,450 ($19.06) to GBX 1,390 ($18.28) and set an “underweight” rating on the stock in a research note on Wednesday, June 28th. HSBC Holdings plc restated a “reduce” rating and issued a GBX 1,800 ($23.67) target price on shares of Hikma Pharmaceuticals Plc in a research note on Tuesday, July 4th. Barclays PLC restated an “overweight” rating and issued a GBX 2,200 ($28.92) target price on shares of Hikma Pharmaceuticals Plc in a research note on Monday, July 3rd. Numis Securities Ltd restated an “add” rating and issued a GBX 1,560 ($20.51) target price on shares of Hikma Pharmaceuticals Plc in a research note on Thursday, August 17th. Finally, J P Morgan Chase & Co restated a “neutral” rating and issued a GBX 1,500 ($19.72) target price on shares of Hikma Pharmaceuticals Plc in a research note on Tuesday, June 27th.

Shares of Hikma Pharmaceuticals Plc (HIK) opened at 1170.00 on Wednesday. The company has a 50-day moving average price of GBX 1,199.19 and a 200 day moving average price of GBX 1,531.27. Hikma Pharmaceuticals Plc has a 1-year low of GBX 1,101.00 and a 1-year high of GBX 2,346.00. The firm’s market capitalization is GBX 2.81 billion.

TRADEMARK VIOLATION WARNING: This news story was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://

A number of equities analysts have weighed in on HIK shares. Jefferies Group LLC decreased their target price on Hikma Pharmaceuticals Plc from GBX 1,450 ($19.06) to GBX 1,390 ($18.28) and set an “underweight” rating on the stock in a research note on Wednesday, June 28th. HSBC Holdings plc restated a “reduce” rating and issued a GBX 1,800 ($23.67) target price on shares of Hikma Pharmaceuticals Plc in a research note on Tuesday, July 4th. Barclays PLC restated an “overweight” rating and issued a GBX 2,200 ($28.92) target price on shares of Hikma Pharmaceuticals Plc in a research note on Monday, July 3rd. Numis Securities Ltd restated an “add” rating and issued a GBX 1,560 ($20.51) target price on shares of Hikma Pharmaceuticals Plc in a research note on Thursday, August 17th. Finally, J P Morgan Chase & Co restated a “neutral” rating and issued a GBX 1,500 ($19.72) target price on shares of Hikma Pharmaceuticals Plc in a research note on Tuesday, June 27th.

Shares of Hikma Pharmaceuticals Plc (HIK) opened at 1170.00 on Wednesday. The company has a 50-day moving average price of GBX 1,199.19 and a 200 day moving average price of GBX 1,531.27. Hikma Pharmaceuticals Plc has a 1-year low of GBX 1,101.00 and a 1-year high of GBX 2,346.00. The firm’s market capitalization is GBX 2.81 billion.

TRADEMARK VIOLATION WARNING: This news story was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://ledgergazette.com/2017/10/11/hikma-pharmaceuticals-plc-hik-given-consensus-rating-of-hold-by-analysts.html.

About Hikma Pharmaceuticals Plc

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.

Analyst Recommendations for Hikma Pharmaceuticals Plc (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply